ScreenerHero

CTNM Contineum Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · contineum-tx.com
12.73USD+0.63%Mkt Cap: 478.92M $P/E: —

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap478.92M USD
Enterprise Value245.93M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-59.98M USD
Revenue/Share—
Last Price12.73 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees51
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.60
PEG—
EV/EBITDA-3.73
EV/Revenue—
P/S—
P/B1.99
EPS (TTM)-1.72
EPS (Forward)-1.92
52W Range
8.60045% of range17.79
52W High17.79 USD
52W Low8.600 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-22.98%
ROA-21.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-55.31M USD
CapEx (TTM)231.00K USD
FCF Margin—
FCF Yield-7.34%
Net Debt-229.98M USD
Net Debt/EBITDA3.48
Balance Sheet
Debt/Equity0.03
Current Ratio37.17
Quick Ratio36.25
Book Value/Sh6.37 USD
Cash/Share6.29 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)22.43 USD
Upside (mean)+76.2%
Target Range17.00 USD – 28.00 USD
17.00+76.2% to mean28.00
# Analysts7
Ownership
Shares Out.32.96M
Float27.70M
Insiders0.07%
Institutions93.17%
Short Interest
Short Ratio5.1d
Short % Float7.45%
Short % Out.6.50%
Shares Short2.44M
Short (prev mo.)2.34M
Technical
SMA 5014.86 (-14.4%)
SMA 20013.71 (-7.2%)
Beta0.86
S&P 52W Chg16.45%
Avg Vol (30d)644.81K
Avg Vol (10d)742.12K
Technical Indicators
RSI (14)41.6
MACD-0.6698
MACD Signal-0.6536
MACD Hist.-0.0162
BB Upper15.67 USD
BB Middle13.46 USD
BB Lower11.24 USD
BB Width32.96%
ATR (14)1.010 USD
Vol Ratio (20d)1.03x